Literature DB >> 11891211

Vascular immunotargeting of glucose oxidase to the endothelial antigens induces distinct forms of oxidant acute lung injury: targeting to thrombomodulin, but not to PECAM-1, causes pulmonary thrombosis and neutrophil transmigration.

Melpo Christofidou-Solomidou1, Stephen Kennel, Arnaud Scherpereel, Rainer Wiewrodt, Charalambos C Solomides, Giuseppe G Pietra, Juan-Carlos Murciano, Sayed A Shah, Harry Ischiropoulos, Steven M Albelda, Vladimir R Muzykantov.   

Abstract

Oxidative endothelial stress, leukocyte transmigration, and pulmonary thrombosis are important pathological factors in acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Vascular immunotargeting of the H(2)O(2)-generating enzyme glucose oxidase (GOX) to the pulmonary endothelium causes an acute oxidative lung injury in mice.(1) In the present study we compared the pulmonary thrombosis and leukocyte transmigration caused by GOX targeting to the endothelial antigens platelet-endothelial cell adhesion molecule (PECAM) and thrombomodulin (TM). Both anti-PECAM and anti-TM delivered similar amounts of (125)I-GOX to the lungs and caused a dose-dependent, tissue-selective lung injury manifested within 2 to 4 hours by high lethality, vascular congestion, polymorphonuclear neutrophil (PMN) sequestration in the pulmonary vasculature, severe pulmonary edema, and tissue oxidation, yet at an equal dose, anti-TM/GOX inflicted more severe lung injury than anti-PECAM/GOX. Moreover, anti-TM/GOX-induced injury was accompanied by PMN transmigration in the alveolar space, whereas anti-PECAM/GOX-induced injury was accompanied by PMN degranulation within vascular lumen without PMN transmigration, likely because of PECAM blockage. Anti-TM/GOX caused markedly more severe pulmonary thrombosis than anti-PECAM/GOX, likely because of TM inhibition. These results indicate that blocking of specific endothelial antigens by GOX immunotargeting modulates important pathological features of the lung injury initiated by local generation of H(2)O(2) and that this approach provides specific and robust models of diverse variants of human ALI/ARDS in mice. In particular, anti-TM/GOX causes lung injury combining oxidative, prothrombotic, and inflammatory components characteristic of the complex pathological picture seen in human ALI/ARDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11891211      PMCID: PMC1867171          DOI: 10.1016/S0002-9440(10)64935-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

Review 1.  Evolving concepts in the pathogenesis of postinjury multiple organ failure.

Authors:  F A Moore; E E Moore
Journal:  Surg Clin North Am       Date:  1995-04       Impact factor: 2.741

2.  Immunotargeting of glucose oxidase: intracellular production of H(2)O(2) and endothelial oxidative stress.

Authors:  A J Gow; F Branco; M Christofidou-Solomidou; L Black-Schultz; S M Albelda; V R Muzykantov
Journal:  Am J Physiol       Date:  1999-08

3.  The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats.

Authors:  N Hasegawa; T G Kandra; A W Husari; S Veiss; W T Hart; J Hedgpeth; R Wydro; T A Raffin
Journal:  Am J Respir Crit Care Med       Date:  1996-06       Impact factor: 21.405

4.  Immunotargeting of antioxidant enzyme to the pulmonary endothelium.

Authors:  V R Muzykantov; E N Atochina; H Ischiropoulos; S M Danilov; A B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

5.  Neutrophil and nonneutrophil-mediated injury in intestinal ischemia-reperfusion.

Authors:  R Simpson; R Alon; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

6.  Anti-transforming growth factor-beta monoclonal antibodies prevent lung injury in hemorrhaged mice.

Authors:  R Shenkar; W F Coulson; E Abraham
Journal:  Am J Respir Cell Mol Biol       Date:  1994-09       Impact factor: 6.914

Review 7.  Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface.

Authors:  C T Esmon
Journal:  FASEB J       Date:  1995-07       Impact factor: 5.191

8.  Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.

Authors:  M Uchiba; K Okajima; K Murakami; K Nawa; H Okabe; K Takatsuki
Journal:  Thromb Haemost       Date:  1995-11       Impact factor: 5.249

9.  Role of leukocyte adhesion molecules in lung and dermal vascular injury after thermal trauma of skin.

Authors:  M S Mulligan; G O Till; C W Smith; D C Anderson; M Miyasaka; T Tamatani; R F Todd; T B Issekutz; P A Ward
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

10.  Aspiration-induced lung injury: role of complement.

Authors:  R Rabinovici; L F Neville; F Abdullah; D R Phillip; J Vernick; K L Fong; L Hillegas; G Feuerstein
Journal:  Crit Care Med       Date:  1995-08       Impact factor: 7.598

View more
  26 in total

Review 1.  Endothelial nanomedicine for the treatment of pulmonary disease.

Authors:  Jacob S Brenner; Colin Greineder; Vladimir Shuvaev; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2014-11-14       Impact factor: 6.648

2.  Endothelial targeting of antibody-decorated polymeric filomicelles.

Authors:  Vladimir V Shuvaev; Marc A Ilies; Eric Simone; Sergei Zaitsev; Younghoon Kim; Shenshen Cai; Abdullah Mahmud; Thomas Dziubla; Silvia Muro; Dennis E Discher; Vladimir R Muzykantov
Journal:  ACS Nano       Date:  2011-08-23       Impact factor: 15.881

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium.

Authors:  Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Arnaud Scherpereel; Eric Simone; Evguenia Arguiri; Samira Tliba; Jeremy Pick; Stephen Kennel; Steven M Albelda; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2007-01-08       Impact factor: 9.776

Review 5.  Nanocarrier Hydrodynamics and Binding in Targeted Drug Delivery: Challenges in Numerical Modeling and Experimental Validation.

Authors:  Portonovo S Ayyaswamy; Vladimir Muzykantov; David M Eckmann; Ravi Radhakrishnan
Journal:  J Nanotechnol Eng Med       Date:  2013-07-11

Review 6.  The Future of Nanoparticle-Directed Venous Therapy.

Authors:  Benjamin Jacobs; Chandu Vemuri
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

Review 7.  Unintended effects of drug carriers: Big issues of small particles.

Authors:  Hamideh Parhiz; Makan Khoshnejad; Jacob W Myerson; Elizabeth Hood; Priyal N Patel; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

8.  Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury.

Authors:  Khalil Bdeir; Kandace Gollomp; Marta Stasiak; Junjie Mei; Izabela Papiewska-Pajak; Guohua Zhao; G Scott Worthen; Douglas B Cines; Mortimer Poncz; M Anna Kowalska
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

Review 9.  Targeted delivery of therapeutics to endothelium.

Authors:  Eric Simone; Bi-Sen Ding; Vladimir Muzykantov
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

Review 10.  Pulmonary endothelium in acute lung injury: from basic science to the critically ill.

Authors:  S E Orfanos; I Mavrommati; I Korovesi; C Roussos
Journal:  Intensive Care Med       Date:  2004-07-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.